RNA-Binding Protein PCBP1/hnRNP E1 is an Intracellular Checkpoint for Shaping Effector Versus Regulatory T Cells in Immunity and Cancer

2019 ◽  
Author(s):  
Ephraim Abrokwa Ansa-Addo ◽  
Huai-Cheng Huang ◽  
Brian Riesenberg ◽  
Supinya Iamsawat ◽  
Davis Borucki ◽  
...  
2020 ◽  
Vol 11 ◽  
Author(s):  
Sohei Makita ◽  
Hiroaki Takatori ◽  
Arifumi Iwata ◽  
Shigeru Tanaka ◽  
Shunsuke Furuta ◽  
...  

2006 ◽  
Vol 17 (8) ◽  
pp. 3521-3533 ◽  
Author(s):  
Linda D. Kosturko ◽  
Michael J. Maggipinto ◽  
George Korza ◽  
Joo Won Lee ◽  
John H. Carson ◽  
...  

Heterogeneous nuclear ribonucleoprotein (hnRNP) A2 is a trans-acting RNA-binding protein that mediates trafficking of RNAs containing the cis-acting A2 response element (A2RE). Previous work has shown that A2RE RNAs are transported to myelin in oligodendrocytes and to dendrites in neurons. hnRNP E1 is an RNA-binding protein that regulates translation of specific mRNAs. Here, we show by yeast two-hybrid analysis, in vivo and in vitro coimmunoprecipitation, in vitro cross-linking, and fluorescence correlation spectroscopy that hnRNP E1 binds to hnRNP A2 and is recruited to A2RE RNA in an hnRNP A2-dependent manner. hnRNP E1 is colocalized with hnRNP A2 and A2RE mRNA in granules in dendrites of oligodendrocytes. Overexpression of hnRNP E1 or microinjection of exogenous hnRNP E1 in neural cells inhibits translation of A2RE mRNA, but not of non-A2RE RNA. Excess hnRNP E1 added to an in vitro translation system reduces translation efficiency of A2RE mRNA, but not of nonA2RE RNA, in an hnRNP A2-dependent manner. These results are consistent with a model where hnRNP E1 recruited to A2RE RNA granules by binding to hnRNP A2 inhibits translation of A2RE RNA during granule transport.


2007 ◽  
Vol &NA; ◽  
pp. S35
Author(s):  
Cristiana Stellato ◽  
J Fang ◽  
B Tancowny ◽  
J Fan ◽  
F Wu ◽  
...  

2007 ◽  
Vol 119 (1) ◽  
pp. S133
Author(s):  
C. Stellato ◽  
X. Fang ◽  
B. Tancowny ◽  
J. Fan ◽  
F. Wu ◽  
...  

2006 ◽  
Vol 177 (7) ◽  
pp. 4426-4435 ◽  
Author(s):  
Timur O. Yarovinsky ◽  
Noah S. Butler ◽  
Martha M. Monick ◽  
Gary W. Hunninghake

2014 ◽  
Vol 20 (1) ◽  
pp. 93-108 ◽  
Author(s):  
Matthew M. Gubin ◽  
Patsharaporn Techasintana ◽  
Joseph D. Magee ◽  
Garrett M. Dahm ◽  
Robert Calaluce ◽  
...  

2014 ◽  
Vol 133 (2) ◽  
pp. AB399
Author(s):  
Ulus Atasoy ◽  
Patsharaporn Techasintana ◽  
Joseph Magee ◽  
Matt Gubin ◽  
Joe Rowles

mBio ◽  
2019 ◽  
Vol 10 (5) ◽  
Author(s):  
Ti-Chun Chao ◽  
Qiong Zhang ◽  
Zhonghan Li ◽  
Shashi Kant Tiwari ◽  
Yue Qin ◽  
...  

ABSTRACT A major challenge in finding a cure for HIV-1/AIDS is the difficulty in identifying and eradicating persistent reservoirs of replication-competent provirus. Long noncoding RNAs (lncRNAs, >200 nucleotides) are increasingly recognized to play important roles in pathophysiology. Here, we report the first genome-wide expression analysis of lncRNAs in HIV-1-infected primary monocyte-derived macrophages (MDMs). We identified an lncRNA, which we named HIV-1-enhanced lncRNA (HEAL), that is upregulated by HIV-1 infection of MDMs, microglia, and T lymphocytes. Peripheral blood mononuclear cells of HIV-1-infected individuals show elevated levels of HEAL. Importantly, HEAL is a broad enhancer of multiple HIV-1 strains because depletion of HEAL inhibited X4, R5, and dual-tropic HIV replications and the inhibition was rescued by HEAL overexpression. HEAL forms a complex with the RNA-binding protein FUS, which facilitates HIV replication through at least two mechanisms: (i) HEAL-FUS complex binds the HIV promoter and enhances recruitment of the histone acetyltransferase p300, which positively regulates HIV transcription by increasing histone H3K27 acetylation and P-TEFb enrichment on the HIV promoter, and (ii) HEAL-FUS complex is enriched at the promoter of the cyclin-dependent kinase 2 gene, CDK2, to enhance CDK2 expression. Notably, HEAL knockdown and knockout mediated by RNA interference (RNAi) and CRISPR-Cas9, respectively, prevent HIV-1 recrudescence in T cells and microglia upon cessation of azidothymidine treatment in vitro. Our results suggest that silencing of HEAL or perturbation of the HEAL-FUS ribonucleoprotein complex could provide a new epigenetic silencing strategy to eradicate viral reservoirs and effect a cure for HIV-1/AIDS. IMPORTANCE Despite our increased understanding of the functions of lncRNAs, their potential to develop HIV/AIDS cure strategies remains unexplored. A genome-wide analysis of lncRNAs in HIV-1-infected primary monocyte-derived macrophages (MDMs) was performed, and 1,145 differentially expressed lncRNAs were identified. An lncRNA named HIV-1-enhanced lncRNA (HEAL) is upregulated by HIV-1 infection and promotes HIV replication in T cells and macrophages. HEAL forms a complex with the RNA-binding protein FUS to enhance transcriptional coactivator p300 recruitment to the HIV promoter. Furthermore, HEAL knockdown and knockout prevent HIV-1 recrudescence in T cells and microglia upon cessation of azidothymidine treatment, suggesting HEAL as a potential therapeutic target to cure HIV-1/AIDS.


Sign in / Sign up

Export Citation Format

Share Document